Caspase-dependent degradation of YTHDF2 governs the epitranscriptomic control of chemotherapy responsiveness by regulating m6A-mediated MYC translation

Cancer cells are masters of survival. When faced with the harsh conditions of a tumor or the attack of a powerful drug, they do not simply give up; they rewire their internal machinery to keep going. One of the most sophisticated ways they do this is by editing the instructions inside their own cells. Inside every cell, DNA acts as the master blueprint, but it is RNA that carries the working copies of those instructions to the factories that build proteins. Recently, scientists discovered that these RNA copies can be chemically marked, much like a highlighter pen marking a specific sentence in a book. This mark, known as m6A, tells the cell how to handle that specific piece of RNA: whether to keep it stable, how fast to translate it into protein, or when to discard it. This system, called the epitranscriptome, is crucial for how cells respond to stress. When chemotherapy attacks a tumor, it causes severe damage, and the cancer cells must quickly decide whether to die or to adapt and resist the treatment. Understanding how these cells manage their RNA instructions during an attack could reveal new ways to stop them from surviving.

A team of researchers at Seoul National University College of Medicine has uncovered a specific mechanism that cancer cells use to survive chemotherapy, a process that involves a protein called YTHDF2 and a famous growth gene called MYC. The study focused on doxorubicin, a widely used chemotherapy drug that works by damaging the DNA of cancer cells. The researchers found that when cells are hit with this drug, they do something unexpected: they actively destroy a group of proteins known as YTHDF readers, which are responsible for reading those chemical marks on RNA. Specifically, the drug triggers a cellular suicide signal that chops up these reader proteins, even though the instructions to make them remain intact. This destruction is not a random side effect of cell damage; it is a deliberate, coordinated response that happens across different types of chemotherapy drugs. The researchers discovered that this process is driven by enzymes called caspases, which are the cell's own executioners, and it occurs independently of another well-known tumor suppressor gene, p53.

Among the proteins that get destroyed, YTHDF2 plays the most critical role in determining whether a cancer cell lives or dies. Under normal conditions, YTHDF2 acts as a bridge. It recognizes the chemical marks on the RNA instructions for the MYC gene and helps the cell's protein-building machinery grab onto those instructions to make more MYC protein. MYC is a powerful driver of cell growth, but in the context of chemotherapy, high levels of MYC actually help the cell commit suicide, which is the desired outcome of the treatment. The researchers showed that when YTHDF2 is present, it boosts the production of MYC protein, making the cell more sensitive to the drug and more likely to die. However, when the chemotherapy drug triggers the destruction of YTHDF2, this bridge is broken. The cell stops making as much MYC protein, even though the RNA instructions for it are still there. This drop in MYC levels allows the cancer cell to escape the lethal effects of the drug, effectively turning off the alarm that would have triggered its own death.

To prove this connection, the scientists conducted a series of experiments in the lab using human colorectal cancer cells. They observed that when they prevented the destruction of YTHDF2, the cells remained highly sensitive to doxorubicin and died quickly. Conversely, when they removed YTHDF2 or blocked its ability to read the chemical marks, the cells became resistant to the drug. The team also confirmed that YTHDF2 does not work by stabilizing the RNA or changing how long it lasts; instead, it specifically helps the cell's machinery translate the RNA into protein more efficiently. They found that the chemical marks on the MYC RNA are essential for this process; if those marks are removed or if the YTHDF2 protein cannot recognize them, the production of MYC protein drops significantly. This mechanism appears to be a survival strategy: by destroying the reader protein, the cancer cell limits the production of the very protein that would otherwise help it die in response to the chemotherapy.

The implications of this discovery extend beyond the laboratory. The researchers analyzed data from thousands of patients with various types of cancer, including lung, colon, and head and neck cancers. They found that patients who had higher levels of YTHDF2 and MYC in their tumors tended to have better outcomes and were more likely to respond to chemotherapy. This suggests that the relationship between these two molecules is not just a cellular curiosity but a real-world factor in how well a patient survives treatment. The study also looked at how different cancer cell lines responded to a wide range of drugs, finding that the levels of YTHDF2 and MYC were consistently linked to how sensitive the cells were to treatment. This indicates that the YTHDF2-MYC axis is a fundamental part of how cancer cells adapt to stress, acting as a switch that can turn the cell's response to chemotherapy from death to survival.

The researchers were careful to rule out other possibilities. They showed that the loss of YTHDF2 proteins was not caused by the cell simply stopping the production of the RNA instructions, nor was it due to the proteins being broken down by the cell's general waste disposal system. Instead, the destruction was specifically caused by the caspase enzymes activated during the cell's stress response. They also demonstrated that this process happens regardless of whether the cancer cells have a working p53 gene, which is a common mutation in many tumors. By isolating this specific pathway, the study provides a clear picture of how a cancer cell can actively remodel its internal language to avoid being killed. The findings suggest that the ability of a tumor to resist chemotherapy is not just about having strong defenses, but about its capacity to rapidly dismantle the very machinery that would make it vulnerable to the treatment.

This work highlights a complex layer of control within cancer cells that operates at the level of RNA translation. It reveals that the cell's response to chemotherapy is not a passive reaction to damage but an active reprogramming of its gene expression. By destroying the YTHDF2 reader, the cell effectively silences the MYC gene's ability to drive the cell toward death, allowing the tumor to persist. The study does not propose a new drug or a cure, but it identifies a specific vulnerability in the way cancer cells adapt. If future treatments could prevent the destruction of YTHDF2 or force the cell to keep reading the MYC instructions, it might be possible to keep the cancer cells sensitive to chemotherapy for longer. The research points to a new way of thinking about drug resistance, suggesting that the key to overcoming it may lie in understanding how cancer cells edit their own instructions to survive. The connection between the chemical marks on RNA, the proteins that read them, and the ultimate fate of the cell offers a concrete target for understanding why some treatments fail and how they might be made to work better.